|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the MDCO 10-Q filed Nov 10, 2008. Sources of Liquidity. Since
our inception, we have financed our operations principally through the sale of
common and preferred stock, sales of convertible promissory notes and warrants,
interest income and revenues from sales of Angiomax. Except for 2006 and 2004,
we have incurred losses on an annual basis since our inception. We had $205.7
million in cash, cash equivalents and available for sale securities as of September 30,
2008.
This excerpt taken from the MDCO 10-Q filed Aug 11, 2008. Sources of Liquidity. Since our
inception, we have financed our operations principally through the sale of common
and preferred stock, sales of convertible promissory notes and warrants,
interest income and revenues from sales of Angiomax. Except for 2006 and 2004,
we have incurred losses on an annual basis since our inception. We had $238.1
million in cash, cash equivalents and available for sale securities as of June 30,
2008.
This excerpt taken from the MDCO 10-Q filed May 12, 2008. Sources of Liquidity. Since
our inception, we have financed our operations principally through the sale of
common and preferred stock, sales of convertible promissory notes and warrants,
interest income and revenues from sales of Angiomax. Except for 2006 and 2004,
we have incurred losses on an annual basis since our inception. We had $216.3
million in cash, cash equivalents and available for sale securities as of March 31,
2008.
This excerpt taken from the MDCO 10-Q filed Nov 8, 2007. Sources
of Liquidity. Since our inception, we
have financed our operations principally through the sale of common and
preferred stock, sales of convertible promissory notes and warrants, interest
income and revenues from sales of Angiomax. Except for 2006 and 2004, we have
incurred losses on an annual basis since our inception. We had $210.2 million
in cash, cash equivalents and available for sale securities as of September 30,
2007.
This excerpt taken from the MDCO 10-Q filed Aug 9, 2007. Sources
of Liquidity. Since our inception, we
have financed our operations principally through the sale of common and
preferred stock, sales of convertible promissory notes and warrants, interest
income and revenues from sales of Angiomax. Except for 2006 and 2004, we have
incurred losses on an annual basis since our inception. We had $216.6 million
in cash, cash equivalents and available for sale securities as of June 30,
2007.
This excerpt taken from the MDCO 10-Q filed May 9, 2007. Sources
of Liquidity. Since our inception, we
have financed our operations principally through the sale of common and
preferred stock, sales of convertible promissory notes and warrants, interest
income and revenues from sales of Angiomax. Except for 2006 and 2004, we have
incurred losses on an annual basis since our inception. We had $193.3 million
in cash, cash equivalents and available for sale securities as of
March 31, 2007.
16 This excerpt taken from the MDCO 10-K filed Mar 1, 2007. Sources
of Liquidity. Since our inception, we
have financed our operations principally through the sale of common and
preferred stock, sales of convertible promissory notes and warrants, interest
income and revenues from sales of Angiomax. Except for 2006 and 2004, we have
incurred losses on an annual basis since our inception. We had $196.8 million
in cash, cash equivalents and available for sale securities as of December 31,
2006.
This excerpt taken from the MDCO 10-Q filed Nov 8, 2006. Sources
of Liquidity. Since our inception, we
have financed our operations through the sale of common and preferred stock,
sales of convertible promissory notes and warrants, interest income and revenue
from sales of Angiomax. With the
exception of the quarterly periods beginning with the fourth quarter of 2003
through the second quarter of 2005 and the second and third quarters of 2006,
we have not been profitable. We had $176.5 million in cash, cash equivalents
and available for sale securities at September 30, 2006.
This excerpt taken from the MDCO 10-Q filed Aug 8, 2006. Sources
of Liquidity. Since our inception, we have financed our
operations through the sale of common and preferred stock, sales of convertible
promissory notes and warrants, interest income and revenue from sales of
Angiomax. With the exception of the
quarterly periods beginning with the third quarter of 2003 through the second
quarter of 2005 and the second quarter of 2006, we have not been profitable. We
had $149.8 million in cash, cash equivalents and available for sale securities
at June 30, 2006.
This excerpt taken from the MDCO 10-Q filed May 10, 2006. Sources of Liquidity. Since
our inception, we have financed our operations through the sale of common and
preferred stock, sales of convertible promissory notes and warrants, interest
income and revenues from sales of Angiomax. With the exception of the quarterly
periods beginning with the third quarter of 2003 through the second quarter of
2005, we have not been profitable. We had $124.2 million in cash, cash
equivalents and available for sale securities at March 31, 2006.
This excerpt taken from the MDCO 10-K filed Mar 15, 2006. Sources of Liquidity. Since our inception, we have
financed our operations principally through the sale of common and preferred
stock, sales of convertible promissory notes and warrants, interest income and
revenues from sales of Angiomax. Except for 2004, we have incurred losses on an
annual basis since our inception. We had $140.1 million in cash, cash
equivalents and available for sale securities as of December 31, 2005.
This excerpt taken from the MDCO 10-Q filed Nov 8, 2005. Sources of Liquidity. Since
our inception, we have financed our operations through the sale of common and
preferred stock, sales of convertible promissory notes and warrants, interest
income and revenues from sales of Angiomax.
With the exception of the quarterly periods beginning with the third
quarter of 2003 through the second quarter of 2005, we have not been profitable.
We had $136.1 million in cash, cash equivalents and available for sale
securities at September 30, 2005.
This excerpt taken from the MDCO 10-Q filed Aug 8, 2005. Sources
of Liquidity. Since
our inception, we have financed our operations through the sale of common and
preferred stock, sales of convertible promissory notes and warrants, interest
income and revenues from sales of Angiomax. In the last seven consecutive
quarters, as we have generated increasing sales of Angiomax, we have been
profitable. We had $145.1 million in
cash, cash equivalents and available for sale securities at June 30, 2005.
This excerpt taken from the MDCO 10-Q filed May 6, 2005. Sources of
Liquidity. Since our inception,
we have financed our operations through the sale of common and preferred stock,
sales of convertible promissory notes and warrants, interest income and
revenues from sales of Angiomax. In the last six consecutive quarters, as we
have generated increasing sales of Angiomax, we have been profitable. We had $153.4 million in cash, cash
equivalents and available for sale securities at March 31, 2005.
This excerpt taken from the MDCO 10-K filed Mar 14, 2005. Sources of Liquidity. Since
our inception, we have financed our operations principally through the sale of
common and preferred stock, sales of convertible promissory notes and warrants,
interest income and revenues from sales of Angiomax. In the last five
consecutive quarters, as we have generated increasing sales of Angiomax, we
have been profitable. In 2004, we achieved profitability on an annual basis for
the first time. We had $160.3 million in cash, cash equivalents and available
for sale securities as of December 31, 2004.
In August and September 2000, we received $101.4 million in net proceeds from the sale of common stock in our initial public offering. Since our initial public offering, we have received an additional $41.8 million in net proceeds in May 2001 from the sale of 4.0 million shares of our common stock in a private placement, $30.9 million in net proceeds in June 2002 from the sale of 4.0 million shares of our common stock in a public offering and $91.5 million in net proceeds in March 2003 from the sale of 5.6 million shares of our common stock in a public offering. Prior to our initial public offering, we had received net proceeds of $79.4 million from the private placement of equity securities, primarily redeemable convertible preferred stock, and $19.4 million from the issuance of convertible notes and warrants. In 2004, employees and a consultant purchased stock pursuant to option exercises and our employee stock purchase plan for aggregate net proceeds to us of approximately $13.7 million. In March 2002, we entered into a collaboration agreement with Nycomed, under which Nycomed serves as the exclusive distributor of Angiox in countries in the European Union other than Greece, Portugal and Spain. Under the agreement Nycomed paid us an initial non-refundable fee of $1.5 million and milestone payments of $2.5 million based on regulatory approvals in Europe. In addition, Nycomed purchased 79,428 shares of our common stock for a total purchase price of approximately $1.0 million. | EXCERPTS ON THIS PAGE:RELATED TOPICS for MDCO: |
| |||||||
